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Introduction
Sarcomas are rare malignant tumors of mesenchymal
origin with 80% originating from soft tissue.1 The ma-
jority of soft tissue sarcomas occur in the extremities;
nevertheless, 10% to 15% occur in the retroperitoneum or
pelvis and are usually advanced at time of diagnosis.2
Oncologic resection with or without perioperative radia-
tion therapy has become the cornerstone for successful
treatment.3-5 The goal of surgery is complete resection
with negative margins (R0 resection). When not possible,
either preoperative or postoperative radiation therapy is
recommended.6-9 Technical challenges related to
anatomic complexities and large tumor size at diagnosis
of most pelvic and retroperitoneal sarcomas often lead to
microscopically positive margins (R1 resection) associ-
ated with high risk of local recurrence.2,10-13 Delivering
adequate doses of radiation in the postoperative setting
represents a significant treatment challenge, especially in
soft tissue sarcomas located in the abdomen, retro-
peritoneum, or pelvic regions.14 In these cases, local
control with preoperative and intraoperative radiation
therapy (IORT) are important considerations.7,8,15
CivaSheet (CivaTech Oncology Inc, Durham, NC) is a
Food and Drug Administrationeapproved bioabsorbable
planar mesh device for IORT low-dose-rate (LDR)
brachytherapy using shielded palladium-103 (103Pd). This
novel device allows directional and customizable radia-
tion therapy, significantly reducing radiation doses to
organs at risk (OARs) with the use of 50 m gold shield
backing (Fig 1A). The directional brachytherapy device is
Content partially presented in the plenary session at the 2016 World
Congress of Brachytherapy and in the poster session at the 2018
American College of Radiation Oncology Annual Meeting.
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manufactured with specified source strengths according to
prescribed doses. The device size and orientation can be
customized in the operating room to conform to the sur-
gical bed. Sufficient dosimetry data and calibration stan-
dards are now available.16-19
The present report describes this treatment approach
and 3-year oncologic outcome of a patient with locally
advanced leiomyosarcoma in the pelvic sidewall who
underwent neoadjuvant pelvic intensity modulated radia-
tion therapy (IMRT) and had a high risk for a positive
margin after resection. The patient was deemed suitable
for IORT20 and, among available technologies in our
institution, LDR brachytherapy with a directional
brachytherapy device was considered superior to other
techniques and devices. Unlike the brachy mesh, Civa-
Sheet requires no additional surgical manipulation of the
omentum or other spacers to keep bowel away from
unshielded seeds given its directionality. Alternative
IORT options include intraoperative electron beam irra-
diation and placement of HDR brachytherapy catheters
were not available.
Materials and Methods
The patient is a 65-year-old black male with an incidental
finding of a left pelvic sidewall mass. During July 2014,
computed tomographic (CT) scan of the abdomen and
pelvis revealed a left pelvic mass measuring
3.5  4.4  5.1 cm. The patient deferred management. In
September 2015, the patient presented with hematuria,
lower abdominal pain, and left flank pain radiating to the left
groin. CT scan of the chest, abdomen, and pelvis, and
magnetic resonance imaging of the pelvis showed an
enlarging lobular, solid, and enhancing necrotic mass
involving the left pelvic musculature. The mass measured
8.1  6.4  7.2 cm with complete encasement on angi-
ography of the left common iliac vein and medial
displacement of the common iliac artery, with no evidence
of distant metastasis (Fig 1B and 1C). Ultrasound-guided
core biopsy revealed a leiomyosarcoma, French Federation
of Comprehensive Cancer Centers (Unicancer; formerly
FNCLCC) grade 2. As discussed in multidisciplinary tumor
board given American Joint Committee on Cancer (seventh
edition) clinical stage IIB (T2bN0M0), tumor grade, and
iliac vein encasement, the patient was recommended pre-
operative pelvic radiation therapy with IMRT, surgical
resection with reconstruction, and an intraoperative LDR
brachytherapy boost. The patient was prescribed 50.4 Gy in
28 fractions to the pelvic mass using IMRT (equivalent dose
[EQD2] Z 49.6). The preoperative plan was delivered in 2
phases. The initial phase with 45 Gy in 25 fractions was
delivered to PTV1, created by expanding the GTV by 2 cm
(anatomic constraint) plus 0.5 cm (geometric expansion). A
reduced field was delivered to PTV2 with an additional
5.4 Gy in 3 fractions, created by expanding the GTV by
0.5 cm (anatomic constraint) plus 0.5 cm (geometric
expansion). The patient was then prescribed a 27.8 Gy
intraoperative boost (physical dose with an
EQD2 Z 17.5 Gy) using the CivaSheet given concerns for
Figure 1 (A) Schematic representation of the CivaSheet, a
flexible brachytherapy device containing 103Pd sources (in blue)
and gold shield backing for directionality (in golden). Computed
tomographic imaging with oral and intravenous contrast in the
(B) coronal and (C) axial views, before the patient received any
treatment. Arrows pointing to left pelvic sidewall tumor.
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microscopic residual disease in the tumor bed (Fig 2).
Summation plan constraints were the following: small
bowel maximal dose <52 Gy, bladder maximal dose
<65 Gy, rectum V50 <50%, and femoral heads V50 <5%.
After completing pelvic IMRT without significant
acute toxicities, the patient underwent exploratory lapa-
rotomy in January 2016 with anticipated R1 resection of
the left pelvic mass. Tumor extension included the
retrosacral space involving the left psoas and iliacus
muscle, underlying pelvic bone, left external and internal
iliac veins and artery, and left ureter. Preoperatively, the
left internal iliac artery was embolized in anticipation of
potential significant blood loss. The left ureter was
involved in the tumor, requiring transection and subse-
quent ureteroneocystostomy. The left external and inter-
nal iliac vein were also grossly involved with the tumor,
Figure 2 Computed tomography-based preimplant dosimetry. (A) Intensity modulated radiation therapy isodose distribution and (B)
dose-volume histograms. (C) Low-dose-rate brachytherapy boost isodose distribution in the anticipated area of positive margins before
resection and (D) dose-volume histograms, where the reference line corresponds to the 17.5 Gy equivalent dose goal, which provided
90% volumetric coverage of the target.
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therefore the left common iliac vein was transected. The
left external iliac artery was not grossly involved with the
tumor but required mobilization secondary to radiation
induced fibrosis. Surgical implantation of the CivaSheet
was performed. The bioabsorbable sheet contained 48
seeds of 103Pd allowing directional irradiation of the
tumor bed while sparing organs at risk, namely the
bladder, rectum, and small bowel. Individual source
strength on the day of implant was 1.06U with total
source strength of 51U and exposure rate of 0.01 mR/h at
Figure 3 Computed tomography-based postimplant dosimetry. (A) Low-dose-rate brachytherapy boost isodose distribution and (B)
corresponding dose-volume histograms.
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1 m. The LDR 103Pd sources are positioned within a
0.8 cm rectilinear matrix (Fig 1A). Radiation dose on the
shielded side of the CivaSheet ranges from a factor of 5 to
24 from 1 to 10 cm, respectively.17
Postimplant CT-based dosimetry in April 2016
confirmed adequate placement of the brachytherapy device
(Fig 3A and 3B). We were pleased with agreement between
the planned and expected implant dosimetry given the
geometric design of the brachytherapy device. The physical
dose was 27.8 Gy to a 0.5 cm depth, BED Z 21.7 Gy, and
EQD2 Z 17.5 Gy (near the center of the desired EQD2
range). Selection of the boost dose was based upon a BED
derivation of 28 Gy physical dose with a Z 0.25 Gy1 and
a/b Z 8.6 Gy values for rhabdomyosarcoma.21 Other
radiobiologic parameters were TPOT Z 23 days,
22 a repair
half-time of 1.5 hours, and an RBE value of unity because
this is a controversial topic. The tumor bed
(CTV Z 4.0 cm3) dosimetric coverage was 99.2%, and the
total EQD2 delivered to the tumor was 67.2 Gy. All OAR
constraints were met, including the bowel constraint goal
with a maximum dose of 49.9 Gy from the preoperative
IMRT plus 1.4 Gy from the CivaSheet implant. After
40 months of serial imaging and clinical follow-up, the
patient experienced no grade 3 þ late radiation therapy
toxicities and no evidence of recurrent disease (Fig 4).
Discussion
This case represents a favorable interval oncologic
outcome in a patient with high-grade leiomyosarcoma of
the pelvic sidewall. He underwent preoperative IMRT, R1
surgical resection (with focally positive margins at the
pelvic side-wall), and IORT boost with the CivaSheet
technology. At 40 months, patient remains free from
locoregional recurrence as evidenced by imaging and
clinical follow-up.
Preoperative radiation therapy is preferred because
it limits toxicity to the bowel, which would unavoid-
ably fall into the treatment field after resection of
tumor. Additionally, lower prescribed dose and smaller
treatment field size is associated with less late radia-
tion therapy-associated toxicities. In this present case,
preoperative radiation therapy with IMRT was fol-
lowed by an intraoperative boost to achieve signifi-
cantly higher doses to the tumor while sparing OARs,
which would have not been possible with IMRT
exclusively. Given the small bowel constraint of a
maximal dose <52 Gy, boost using IMRT or post-
operative doses of 60 to 66 Gy would have exceeded
the dose tolerance, and thus requirement for conformal
brachytherapy boost.
Preoperative radiation therapy with IORT offers
unique advantages for select patients with abdominal,
retroperitoneal, or pelvic sarcomas.7,8 However, IORT is
dependent on institutional practice and resources and may
not be widely available.23 CivaSheet expands IORT ca-
pabilities in a resource independent manner. In the case
presented herein, using preoperative IMRT and CivaSheet
was associated with durable local control and significant
reduction in doses to OARs including bowel, rectum, and
bladder.17,24
Figure 4 Computed tomographic imaging with oral and intravenous contrast in the (A) coronal and (B) axial views at 28 months after
resection and with intravenous contrast only in the (C) coronal and (D) axial views at 30 months after resection. No evidence of
recurrence in any of the serial imaging performed. Arrows pointing to the implanted CivaSheet device.
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Results from the use of CivaSheet may be comparable
to published contemporary analysis of retroperit1al soft
tissue sarcoma resection and perioperative radiation
therapy with 3-year local recurrence of approximately 5%
to 15%.25,26 Limitations to this study are attributed to
results from a single patient with a modest follow-up;
however, this report and a growing cohort of 66
patients who have now undergone CivaSheet IORT
(personal communication, December 2018) support this
treatment paradigm. Malignancies previously treated with
this device include breast, colorectal, lung, pancreatic,
sarcoma, head and neck, chest wall, thoracic, abdominal,
pelvic, gynecologic, prostatic, and axillary malignancies,
in both definitive and salvage settings. To our knowledge,
this is the first report of a patient undergoing CivaSheet
treatment for leiomyosarcoma of the pelvic sidewall.
Advantages include directional irradiation attributed to
gold shielding on 1 side of the 103Pd source and cus-
tomization of its size and shape. Moreover, the directional
nature of this device helps increase the therapeutic ratio
by avoiding unnecessary irradiation of OARs. The bio-
absorbability, flexibility, and easy identification on CT
imaging allow this device to treat tumors in irregularly
shaped cavities, such as the pelvic sidewall and retro-
peritoneum. The device seems to be a safe option in select
patients requiring preoperative radiation therapy with
addition of a boost. In this patient, we favored boost de-
livery via IORT (as opposed to IMRT) because this
focused approach allowed sparing of OARs. Additionally,
positioning of the device demarcates the area that received
boost and serves as an anatomic reference for surveillance
of local tumor recurrence. CivaSheet requires coordina-
tion among multidisciplinary teams while understanding
the novelty of this device for directional brachytherapy
treatment planning.
Favorable results and considerable range of potential
applications have driven ongoing and future research. The
ClinicalTrials.gov website lists 4 phase 1 and 2 studies
evaluating the CivaSheet device. These trials include 3
currently accruing: 2 for pancreatic cancer
(NCT02843945 and NCT03109041) and 1 for prostate
cancer (NCT03657108). Additionally, 2 trials are active
but not accruing yet: 1 for abdomino-pelvic solid tumors
(NCT02902107) and 1 for lung cancer (NCT03290534).
Conclusions
In this patient with a pelvic soft tissue sarcoma, pre-
operative radiation therapy followed by intraoperative
LDR brachytherapy using the CivaSheet offers durable
local control. This favorable interval outcome occurred
despite a focally positive microscopic margin while
concomitantly sparing toxicity to critical pelvic OARs.
Additional ongoing studies may guide patient selection
for this promising brachytherapy technology.
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